Xue, Gang
Xie, Jianing
Hinterndorfer, Matthias http://orcid.org/0000-0003-2435-4690
Cigler, Marko http://orcid.org/0000-0003-1861-7968
Dötsch, Lara http://orcid.org/0000-0001-8100-5636
Imrichova, Hana http://orcid.org/0000-0003-0385-1823
Lampe, Philipp
Cheng, Xiufen
Adariani, Soheila Rezaei
Winter, Georg E. http://orcid.org/0000-0001-6606-1437
Waldmann, Herbert http://orcid.org/0000-0002-9606-7247
Funding for this research was provided by:
Max-Planck-Gesellschaft
Alexander von Humboldt-Stiftung
Austrian Science Fund (P32125, P31690, P7909, P32125, P31690, P7909)
Article History
Received: 20 March 2023
Accepted: 15 November 2023
First Online: 30 November 2023
Competing interests
: G.E.W. is scientific founder and shareholder of Proxygen and Solgate. The Winter lab received research funding from Pfizer. The remaining co-authors declare no conflicts of interest to disclose.